ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 ↗

March 09, 2024

Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.

Via InvestorPlace

Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗

February 09, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

Via Investor's Business Daily

ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading

February 08, 2024

Via Investor Brand Network

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 ↗

February 06, 2024

Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗

February 06, 2024

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall ↗

February 02, 2024

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 01, 2024

From ImmunoGen, Inc.

Via Business Wire

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

Via Get News

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures ↗

January 29, 2024

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.

Via Benzinga

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

--News Direct--

Via News Direct

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...

Via TheNewswire.com

ABBV: This Top Biotech Just Went On A Buying Spree ↗

January 25, 2024

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

Via Talk Markets

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

7 Dividend Aristocrats That Will Pay You for Years to Come ↗

January 22, 2024

If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.

Via InvestorPlace

Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 ↗

January 18, 2024

On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.

Via Investor's Business Daily

Cassava Sciences Stock Continues Showing Rising Relative Strength ↗

January 16, 2024

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

Via Investor's Business Daily

Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things' ↗

January 08, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted.

Via Benzinga

Is AbbVie Stock a Buy Now? ↗

January 07, 2024

The company is grappling with losing Humira's patent protection in 2023.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 03, 2024

From ImmunoGen, Inc.

Via Business Wire

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why ↗

December 26, 2023

The acquisition fills an immediate need with some extras to boot.

Via The Motley Fool

3 Stocks at the Forefront of Medical Innovation ↗

December 25, 2023

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Via InvestorPlace

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

December 21, 2023

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

Via Investor's Business Daily

The 7 Most Undervalued Growth Stocks to Buy in December ↗

December 13, 2023

Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback.

Via InvestorPlace

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days ↗

December 13, 2023

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.